Brazilian Journal of Cardiovascular Surgery

BJCVS Journal Club – Live Scientific Discussion

The Brazilian Journal of Cardiovascular Surgery (BJCVS) invites you to a new edition of the BJCVS Journal Club.

Featured article:
Sixty-Two Years of Internal Mammary Artery Grafting and Forty Years of a Milestone Paper

Authors:
Andrea Cristina Oliveira Freitas; Henrique Murad

Moderator:
Dr. Nelson Hossne – Co-Editor-in-Chief of BJCVS

Date & Time:
July, 01 | 8:00 PM (BRT)

Where to Watch:
Live on Instagram @‌bjcvs

Target audience:
Cardiovascular surgeons, perfusionists, pediatric cardiology teams, residents, students, healthcare professionals, and general audience.

Read the article: https://bit.ly/4eC76WW

O BJCVS, em comemoração aos seus 40 anos, oferece aos acadêmicos do DBLACCV (Departamento Brasileiro de Ligas Acadêmicas em Cirurgia Cardiovascular) uma oportunidade exclusiva de capacitação científica.

📚 Aulas gravadas
💻 Oficina online ao vivo
🎓 Certificado de conclusão
✅ Participação gratuita

Transforme conhecimento em produção científica de impacto! 📝❤️

Inscreva-se: https://cursos.sbccv.org.br/curso-de-producao-cientifica-para-academicos

O BJCVS, em comemoração aos seus 40 anos, oferece aos acadêmicos do DBLACCV (Departamento Brasileiro de Ligas Acadêmicas em Cirurgia Cardiovascular) uma oportunidade exclusiva de capacitação científica.

📚 Aulas gravadas
💻 Oficina online ao vivo
🎓 Certificado de conclusão
✅ Participação gratuita

Transforme conhecimento em produção científica de impacto! 📝❤️

Versão mais curta para o card:

🎓 Curso de Produção Científica para Acadêmicos

Exclusivo para acadêmicos do DBLACCV.

📚 Aulas gravadas | 💻 Oficina ao vivo | 🎓 Certificado | ✅ Gratuito

Uma iniciativa especial dos 40 anos do BJCVS. 🚀📖

Inscreva-se: https://cursos.sbccv.org.br/curso-de-producao-cientifica-para-academicos

Big News from BJCVS 🎉

The Brazilian Journal of Cardiovascular Surgery (BJCVS) has just reached a new milestone: our Impact Factor is now 1.4, up from 1.2.

This rise reflects the dedication of our authors, reviewers, editorial board, and readers who keep choosing BJCVS to share and discuss high-quality cardiovascular research.

Thank you for being part of this journey. There’s still a lot of work ahead, and we’re grateful to do it alongside such a strong community.

🔗 Read more at www.bjcvs.org

Receber o diagnóstico de doença coronariana costuma trazer uma dúvida imediata: qual é o melhor tratamento?

Nem sempre a resposta é stent ou cirurgia. Em muitos casos, o tratamento clínico otimizado, associado a mudanças no estilo de vida e ao uso adequado de medicamentos, é a base para controlar os sintomas e reduzir o risco de complicações.

Quando necessário, a angioplastia com stent ou a cirurgia de revascularização do miocárdio (ponte de safena) podem oferecer benefícios importantes. A escolha depende das características de cada paciente, da complexidade das lesões e dos objetivos do tratamento.

Mais do que tratar obstruções, o objetivo é proporcionar mais qualidade de vida e melhores resultados a longo prazo.

Leia a matéria completa no Blog do BJCVS:
🔗 https://bit.ly/4eOYqxu

Levosimendan vs. Intra-Aortic Balloon Pump in Coronary Artery Bypass Grafting: A Meta-Analysis

autores: Yanjie Wang1 #; Jinluan Qu2 #; Dan Sheng1; Xiang Sun3; Liqin Zhong1; Yingjie Wu1; Hao Liang1

A meta-analysis published in the Brazilian Journal of Cardiovascular Surgery (9 studies, 681 patients) compared the efficacy and safety of Levosimendan (pharmacological support) versus an Intra-Aortic Balloon Pump (IABP) (mechanical support) in patients with reduced left ventricular function undergoing CABG.

Advantages of Levosimendan:

• Faster recovery: It reduced ICU stay (by an average of 0.83 days) and led to earlier hospital discharge (by an average of 1.14 days).

• Respiratory support: It showed a trend toward reducing mechanical ventilation time.

• Hemodynamic control: It maintained significantly lower and more controlled Mean Arterial Pressure (MAP) levels compared to the IABP.

• Age Analysis: In patients under 60 years old, Levosimendan demonstrated superior protection against postoperative Atrial Fibrillation (AF).

• No significant differences: Both methods showed similar outcomes regarding in-hospital mortality and the need for additional inotropic support.

• Adverse effects: The Levosimendan group showed a numerically higher rate of postoperative mediastinitis, though this finding lacked definitive statistical significance.

Levosimendan is a robust alternative to IABP, capable of accelerating postoperative recovery and improving hemodynamic control in high-risk patients. However, its use still requires individualized assessment due to variations in administration protocols.

Did you find this insight helpful? What has been your practical experience in the ICU with these two options? Share your thoughts in the comments!

Link artigo: https://bit.ly/4vbmoJk

June 12th: National Congenital Heart Disease Awareness Day  

Did you know that Congenital Heart Disease (CHD) affects roughly 1 in every 100 live births? In Brazil, thousands of children are born with cardiac malformations yearly, and nearly 80% will need surgical intervention. 

Data from the Brazilian Journal of Cardiovascular Surgery (BJCVS) reinforces that saving these little hearts relies on a well-coordinated triad: 

Early Screening & Prenatal Diagnosis: Fetal echocardiography and pulse oximetry are vital. Detecting anomalies before birth allows for planned delivery at specialized centers, dramatically reducing neonatal mortality. 

Surgical Innovation: From complex neonatal repairs (like Norwood or Jatene) to tailored cardiopulmonary bypass (CPB) strategies, advancements in pediatric cardiovascular surgery have greatly reduced postoperative morbidity. 

Lifelong Follow-up: As surgical outcomes improve, most children now reach adulthood. This creates a growing population of “Grown-Up Congenital Heart” (GUCH) patients who require continuous specialized care. 

Our commitment: Foster high-quality research, improve access to specialized care, and give these brave children a real chance at a healthy future.  

Explore the latest surgical outcomes and epidemiology of CHD in Brazil at: https://bit.ly/4uvbxsq  

Utility of the Charlson Comorbidity Index in the Preoperative Evaluation of Patients Undergoing Cardiac Surgery

In cardiac surgery, assessing patient risk goes far beyond heart health. A recent study published in the BJCVS evaluated the utility of the Charlson Comorbidity Index (CCI) in predicting postoperative outcomes, and the results are a must-read for surgical planning.

Key Findings: Patients with severe comorbidity (CCI ≥ 3) showed significantly higher rates of:

Delirium: 27.3% vs. 9.4% in mild cases.

Nosocomial Pneumonia: 3x higher risk.

Renal Replacement Therapy: Over 4x higher risk.

Why use the CCI? While traditional cardiac scores (like EuroSCORE or STS) focus on heart-specific factors, the CCI evaluates the total burden of chronic conditions (Diabetes, CKD, COPD, etc.).

The Bottom Line: Integrating the CCI into routine preoperative evaluation allows for better risk stratification and personalized care pathways. Identifying high-risk patients early is the key to optimizing resources and, most importantly, improving survival.

Read the article: https://bit.ly/3PGL1xP